195 related articles for article (PubMed ID: 23253664)
1. Effect of propranolol as antiadhesive therapy in sickle cell disease.
De Castro LM; Zennadi R; Jonassaint JC; Batchvarova M; Telen MJ
Clin Transl Sci; 2012 Dec; 5(6):437-44. PubMed ID: 23253664
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo.
Zennadi R
PLoS One; 2014; 9(10):e110306. PubMed ID: 25330306
[TBL] [Abstract][Full Text] [Related]
3. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo.
Zennadi R; Moeller BJ; Whalen EJ; Batchvarova M; Xu K; Shan S; Delahunty M; Dewhirst MW; Telen MJ
Blood; 2007 Oct; 110(7):2708-17. PubMed ID: 17609430
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo.
McMahon TJ; Shan S; Riccio DA; Batchvarova M; Zhu H; Telen MJ; Zennadi R
Blood Adv; 2019 Sep; 3(17):2586-2597. PubMed ID: 31484636
[TBL] [Abstract][Full Text] [Related]
5. RNA aptamer therapy for vaso-occlusion in sickle cell disease.
Burnette AD; Nimjee SM; Batchvarova M; Zennadi R; Telen MJ; Nishimura J; Sullenger BA
Nucleic Acid Ther; 2011 Aug; 21(4):275-83. PubMed ID: 21793788
[TBL] [Abstract][Full Text] [Related]
6. Disrupting the vicious cycle created by NOX activation in sickle erythrocytes exposed to hypoxia/reoxygenation prevents adhesion and vasoocclusion.
MacKinney A; Woska E; Spasojevic I; Batinic-Haberle I; Zennadi R
Redox Biol; 2019 Jul; 25():101097. PubMed ID: 30661992
[TBL] [Abstract][Full Text] [Related]
7. MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease.
Zhao Y; Schwartz EA; Palmer GM; Zennadi R
FASEB J; 2016 Mar; 30(3):1171-86. PubMed ID: 26631480
[TBL] [Abstract][Full Text] [Related]
8. Prior exposure of endothelial cells to hydroxycarbamide alters the flow dynamics and adhesion of sickle red blood cells.
Verger E; Schoëvaërt D; Carrivain P; Victor JM; Lapouméroulie C; Elion J
Clin Hemorheol Microcirc; 2014; 57(1):9-22. PubMed ID: 24002118
[TBL] [Abstract][Full Text] [Related]
9. Gαs proteins activate p72(Syk) and p60-c-Src tyrosine kinases to mediate sickle red blood cell adhesion to endothelium via LW-αvβ3 and CD44-CD44 interactions.
Chiou E; Zennadi R
Int J Biochem Cell Biol; 2015 Aug; 65():40-51. PubMed ID: 26007235
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
11. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions.
Zennadi R; Hines PC; De Castro LM; Cartron JP; Parise LV; Telen MJ
Blood; 2004 Dec; 104(12):3774-81. PubMed ID: 15308566
[TBL] [Abstract][Full Text] [Related]
12. Mn porphyrins as a novel treatment targeting sickle cell NOXs to reverse and prevent acute vaso-occlusion in vivo.
Thamilarasan M; Estupinan R; Batinic-Haberle I; Zennadi R
Blood Adv; 2020 Jun; 4(11):2372-2386. PubMed ID: 32479589
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
Almeida CB; Scheiermann C; Jang JE; Prophete C; Costa FF; Conran N; Frenette PS
Blood; 2012 Oct; 120(14):2879-88. PubMed ID: 22833547
[TBL] [Abstract][Full Text] [Related]
14. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
Cartron JP; Elion J
Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
[TBL] [Abstract][Full Text] [Related]
15. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
[TBL] [Abstract][Full Text] [Related]
16. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
[TBL] [Abstract][Full Text] [Related]
17. Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia.
Belcher JD; Gomperts E; Nguyen J; Chen C; Abdulla F; Kiser ZM; Gallo D; Levy H; Otterbein LE; Vercellotti GM
PLoS One; 2018; 13(10):e0205194. PubMed ID: 30308028
[TBL] [Abstract][Full Text] [Related]
18. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease.
Canalli AA; Franco-Penteado CF; Traina F; Saad ST; Costa FF; Conran N
Eur J Haematol; 2007 Oct; 79(4):330-7. PubMed ID: 17680813
[TBL] [Abstract][Full Text] [Related]
19. Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.
Telen MJ; Batchvarova M; Shan S; Bovee-Geurts PH; Zennadi R; Leitgeb A; Brock R; Lindgren M
Br J Haematol; 2016 Dec; 175(5):935-948. PubMed ID: 27549988
[TBL] [Abstract][Full Text] [Related]
20. Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.
Chaar V; Laurance S; Lapoumeroulie C; Cochet S; De Grandis M; Colin Y; Elion J; Le Van Kim C; El Nemer W
J Biol Chem; 2014 Apr; 289(16):11512-11521. PubMed ID: 24616094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
